| アブストラクト | BACKGROUND: Some case reports have described parkinsonism with amiodarone. We investigated a putative association between parkinsonism and exposure to amiodarone. METHODS: We used the WHO pharmacovigilance database (VigiBase((R)) ). All adverse drug reactions with 'Parkinson-like events' and amiodarone were included. Four disproportionality analyses were performed: 1/after inclusion of all reports, 2/according to sex, 3/for the twenty last years (2000-2019), and 4/after exclusion of concomitant drugs known to induce parkinsonism (antipsychotic, antivertigo, antiemetic antinauseant drugs, flunarizine). Results are expressed as reporting odds ratios (ROR; 95% CI) and information component (IC). RESULTS: No significant association was found in the whole population [ROR = 0.83 (0.65-1.06), IC = -0.7 (IC025 = -0.65)], in men, in women, for the 2000-2019 years, or after exclusion of drugs inducing parkinsonism. CONCLUSION: We failed to find any signal of parkinsonism with amiodarone. We suggest that reports of parkinsonism with amiodarone could be mainly explained by other underlying causes. |
|---|
| ジャーナル名 | Fundamental & clinical pharmacology |
|---|
| Pubmed追加日 | 2020/10/25 |
|---|
| 投稿者 | Montastruc, Jean-Louis; Durrieu, Genevieve |
|---|
| 組織名 | Service de Pharmacologie Medicale et Clinique, Centre de PharmacoVigilance, de;Pharmaco-epidemiologie et d'Informations sur le Medicament de Toulouse, CIC;INSERM 1426, Faculte de Medecine, Centre Hospitalier Universitaire, Toulouse,;France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33098706/ |
|---|
